Immunosuppressive therapy alters the host-tumor relationship by inhibition of IL-2 stimulated T-cell proliferation, enhancement of tumor angiogenesis, and a dose-dependent reduction in DNA repair capability, resulting in increased biologic aggressiveness, and likely explains why transplantation confers a poor prognosis for cancer outcomes [11]. Here, IL2 is linked to cancer.